Predictive Oncology Inc. (POAI) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
POAI Revenue Growth
Revenue Breakdown (FY 2024)
POAI's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
POAI Revenue Analysis (2013–2024)
As of May 8, 2026, Predictive Oncology Inc. (POAI) generated trailing twelve-month (TTM) revenue of $728,195, reflecting significant decline in growth of -99.0% year-over-year. The most recent quarter (Q3 2025) recorded $3,618 in revenue, up 34.9% sequentially.
Looking at the longer-term picture, POAI's 5-year compound annual growth rate (CAGR) stands at +2.8%, indicating moderate growth over time. The company achieved its highest annual revenue of $1.6 million in 2023.
Revenue diversification analysis shows POAI's business is primarily driven by Pittsburgh (100%). With over half of revenue concentrated in Pittsburgh, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RXRX (+11.0% YoY), ABSI (-66.3% YoY), and SDGR (+10.6% YoY), POAI has underperformed the peer group in terms of revenue growth. Compare POAI vs RXRX →
POAI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| POAICurrent | $728,195 | -99.0% | +2.8% | -673.7% | |
 RXRX | $75M | +11.0% | +85.4% | -867.9% | |
 ABSI | $3M | -66.3% | -10.1% | -4454.2% | |
 SDGR | $256M | +10.6% | +18.8% | -65.2% | |
 ACLX | $22M | -79.4% | - | -1135.6% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% |
POAI Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.6M | -0.2% | $798K | 49.1% | $-10,939,470 | -673.7% |
| 2023 | $1.6M | +8.1% | $1.0M | 62.6% | $-12,117,736 | -744.5% |
| 2022 | $1.5M | +6.0% | $1.0M | 66.4% | $-26,033,652 | -1729.3% |
| 2021 | $1.4M | +13.4% | $934K | 65.7% | $-20,428,631 | -1437.9% |
| 2020 | $1.3M | -11.3% | $805K | 64.3% | $-25,360,037 | -2025.1% |
| 2019 | $1.4M | -0.0% | $880K | 62.3% | $-22,644,743 | -1604.2% |
| 2018 | $1.4M | +115.6% | $996K | 70.5% | $-7,861,379 | -556.9% |
| 2017 | $655K | +43.4% | $507K | 77.4% | $-7,746,593 | -1183.0% |
| 2016 | $456K | -30.2% | $275K | 60.2% | $-6,526,011 | -1429.6% |
| 2015 | $654K | -31.2% | $350K | 53.5% | $-4,399,643 | -672.4% |
See POAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs POAI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare POAI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPOAI — Frequently Asked Questions
Quick answers to the most common questions about buying POAI stock.
Is POAI's revenue growth accelerating or slowing?
POAI revenue declined -99.0% year-over-year, contrasting with the 5-year CAGR of +2.8%. TTM revenue fell to $728195.00. This reverses the prior growth trend.
What is POAI's long-term revenue growth rate?
Predictive Oncology Inc.'s 5-year revenue CAGR of +2.8% reflects the variable expansion pattern. Current YoY growth of -99.0% is below this long-term average.
How is POAI's revenue distributed by segment?
POAI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.